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Background
Evaluation of changes in lipid ratios and tools such as the
Framingham risk equation may provide a more compre-
hensive measure of the implications of lipid changes.
Methods
664 ARV-naive HIV-1-infected subjects were randomized
1:1:1:1 to lopinavir/ritonavir (LPV/r) once-daily (QD)
SGC, twice-daily (BID) SGC, QD tablet, BID tablet for
eight weeks. All subjects received tenofovir (TDF) +
emtricitabine (FTC) QD. At week 8, subjects taking LPV/r
SGC were switched to the tablet formulation while main-
taining their QD or BID dosing schedule. All subjects will
be followed for up to 96 weeks. Metabolic evaluations at
baseline (BL) and week 48 are presented.
Summary of results
BL characteristics were similar between QD and BID
groups. Through 48 weeks, 15% (QD) and 17% (BID)
discontinued prematurely for various reasons. Only two
patients discontinued due to either elevated triglyceride
(TG) or total cholesterol (TC) levels. Statistically signifi-
cant mean increases were observed in individual lipid
parameters through 48 weeks (Table 1). However, among
all subjects combined, decreases through 48 weeks were
observed for both TC:HDL ratio (from 4.40 to 4.21, p =
0.102) and LDL:HDL ratio (from 2.69 to 2.34, p < 0.001).
80% of subjects overall who had TG values < 2.825
mmol/L at BL maintained these levels at week 48. Of sub-
jects who had TC in the desirable NCEP range (< 5.2
mmol/L) at BL, 72% maintained these levels at week 48.
87% of subjects who had LDL in the optimal/near opti-
mal NCEP range (< 3.38 mmol/L) at BL also had levels in
this range at week 48. The proportion of subjects with low
HDL (<1.04 mmol/L) by NCEP decreased from 60% to
33% from BL to week 48. The mean 10-year CV risk,
including the effect of the change in age over 48 weeks,
remained unchanged over 48 weeks when the LDL criteria
were used (4.63% to 4.60%, p = 0.750), but increased
slightly when the TC criteria were used (4.25% to 5.02%,
p < 0.001). HOMA did not significantly change from base-
line to week 48 (mean change +0.06).
Conclusion
Measures of lipid ratios and Framingham models are bet-
ter assessments of cardiovascular risk than individual lipid
parameters. Through 48 weeks, in subjects treated with a
LPV/r-based regimen, these measures (TC:HDL and LDL-
C:HDL ratios) and Framingham (TC-based and LDL-
based) 10-year cardiovascular risk were minimally
impacted.
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Table 1: Mean basline (BL), week 48, and changes from BL in lipid parameters.
Overall (N = 568 to 575) QD (N = 290 to 295) BID (N = 276 to 280)
TC (mmol/L) BL, Wk48, Δ 4.00, 4.82, +0.82 4.02, 4.77, +0.75 3.97, 4.87, +0.89
TG (mmol/L) BL, Wk48, Δ 1.74, 2.35, +0.61 1.71, 2.22, +0.51 1.76, 2.48, +0.72
LDL (mmol/L) BL, Wk48, Δ 2.50, 2.69, +0.19 2.53, 2.67, +0.14 2.47, 2.71, +0.24
HDL (mmol/L) BL, Wk48, Δ 1.02, 1.21, +0.19 1.03, 1.22, +0.19 1.01, 1.20, +0.19
TC:HDL ratio BL Wk48, Δ 4.40, 4.21, -0.20 4.46, 4.11, -0.35 4.34, 4.31, -0.03
LDL:HDL ratio BL, Wk48, Δ 2.69, 2.34, -0.35 2.74, 2.31, -0.43 2.64, 2.38, -0.27
10-yr CHD risk (LDL) (%) BL, Wk48, Δ 4.63, 4.60, -0.04 4.49, 4.43, -0.06 4.77, 4.76, -0.01
10-yr CHD risk (TC) (%) BL, Wk48, Δ 4.25, 5.02, +0.78 4.29, 4.89, +0.60 4.21, 5.17, +0.96Page 2 of 2
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